
Panelists discuss the OlympiA trial, evaluating adjuvant olaparib post-neoadjuvant chemotherapy in patients with germline BRCA1/BRCA2 mutations and high-risk HER2-negative breast cancer, and its impact on treatment outcomes.
Laura Huppert, MD, is an assistant professor of medicine at the University of California San Francisco.

Panelists discuss the OlympiA trial, evaluating adjuvant olaparib post-neoadjuvant chemotherapy in patients with germline BRCA1/BRCA2 mutations and high-risk HER2-negative breast cancer, and its impact on treatment outcomes.

Panelists discuss the exploratory biomarker analysis from the KEYNOTE-522 trial, comparing perioperative pembrolizumab versus placebo plus chemotherapy in early-stage breast cancer, and its implications for treatment strategies.

Panelists discuss the INSEMA trial, comparing no axillary surgery versus axillary sentinel lymph node biopsy (SLNB) in patients with early invasive breast cancer, exploring the implications for treatment decisions and patient outcomes.

Laura Huppert, MD, discusses a real-world study looking at the implications for using sequential ADCs in patients with breast cancer.

Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, provide closing thoughts on the evolving treatment landscape for HER-negative and HER2-low metastatic breast cancer.

Medical oncologists share clinical practices for selecting and sequencing TROP2-directed antibody-drug conjugates, highlighting ideal candidates for sacituzumab govitecan or datopotamab deruxtecan.

Experts on breast cancer offer comprehensive insights on findings from the TROPiCS-02 study investigating sacituzumab govitecan in patients with HR+/HER2- metastatic or locally recurrent inoperable breast cancer.

Breast cancer specialists review the study design, efficacy data, and safety profile findings from the TROPION-Breast01 study investigating datopotamab deruxtecan (Dato-DXd) in patients with HR+/HER2- metastatic breast cancer.

Medical oncologists provide insights on emerging pathways and TROP2-directed antibody-drug conjugates in HR+/HER2- metastatic breast cancer, highlighting ongoing research.

Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, share advice for community oncologists on the utilization of T-DXd and discuss the future outlook for antibody-drug conjugates in HR+/HER2-low breast cancer.

Experts on breast cancer describe the best candidates for HER2-directed antibody-drug conjugates in HR+/HER2-low metastatic breast cancer, highlighting the role of trastuzumab deruxtecan in later lines of therapy.

Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, discuss treatment sequencing practices and ongoing challenges in patients with HR+/HER2-low breast cancer.